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Background: Extended spectrum beta-lactamase-producing Klebsiella pneumoniae (ESBL-Kp) infection can cause
significant morbidity and mortality in neonates. We investigated a nosocomial ESBL-Kp outbreak in a neonatal
intensive care unit (NICU) of the University Hospital of Larissa (UHL), Central Greece.
Methods: A total of sixty-four ESBL-Kp were studied; twenty six isolates were recovered from the NICU and were
compared with thirty-eight randomly selected isolates from different wards of the hospital during the period
March- December 2012. All isolates were characterized by antimicrobial susceptibility testing, ESBL-production by
double-disk synergy test, molecular typing using BOX-PCR, whereas selected isolates were further characterized by
beta lactamase and virulence gene content, multilocus sequence typing and phylogenetic analysis. All neonates
affected by ESBL-Kp were put under strict contact isolation, along with appropriate infection control measures.
Results: The outbreak strain of ST20 multidrug-resistant SHV-5-producing K. pneumoniae was identified in all
infected (n = 13) and three colonized neonates. A novel ST (ST1114) was also identified among SHV-5 producers
(n = 10) recovered from nine colonized infants, but it was not related with ST20. Both STs were identified only in
the NICU and not in other wards of the hospital. No ESBL-Kp were isolated from the hands of the nursing staff and
the environment. Although we were not able to identify the source of the outbreak, no ESBL-Kp were isolated in
the NICU after this period and we assumed that the outbreak was successfully controlled. All neonates received
parenteral nutrition and most of them were delivered by caesarean section and showed low gestational age
(<32 weeks) and low birth weights (<1500 g).
Conclusion: According to our knowledge, this is the first description of an outbreak of multidrug-resistant SHV-5
producing K. pneumoniae assigned to ST20.
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Klebsiella pneumoniae is an opportunistic pathogen re-
sponsible for nosocomial infections. The microorganisms
are isolated more frequently from the stool, umbilical cord
and the oropharynx. Bloodstream infections caused by
K. pneumoniae are also often reported in the neonatal in-
tensive care units (NICUs) [1]. Transmission can occur* Correspondence: petinaki@med.uth.gr
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unless otherwise stated.either from the mother to child at birth, or acquired du-
ring nursery by person-to-person transmission, via the
hands of the nursing staff and the contaminated equip-
ment, food or the environment.
In K. pneumoniae, acquired resistance to penicillins,
broad spectrum cephalosporins and monobactams, except
for carbapenems and cephamycins can be mediated by the
production of extended-spectrum beta-lactamases (ESBLs).
The most widespread ESBLs belong to the TEM, SHV and
CTX-M families [2-5]. Choice of antibiotic therapy may be
limited if the organism produces an ESBL, particularly for
pneumonias. Nosocomial outbreaks of extended-spectrumal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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increased morbidity and mortality have been frequently re-
ported, mostly in debilitated, hospitalized patients in the in-
tensive care units (ICUs) and neonatal units [2-11].
During 2012, the emergence and spread of ESBL-Kp was
documented in the neonatal intensive care unit (NICU) of
the University Hospital of Larissa (UHL), Central Greece.
We report here, the epidemiological features, molecular
characterization of the beta-lactamase and virulence gene
content, molecular epidemiology by BOX-PCR and multi-
locus sequence typing (MLST), and control measures for
the outbreak of multidrug-resistant SHV-5 producers.
Methods
Setting and definition of cases
The UHL serves as one of the main (600-beds) tertiary
care hospitals in the district of Thessaly, (1,000,000 inhabi-
tants). The NICU of UHL receives approximately 750 ad-
missions per year and it has six rooms (40 beds) for
newborns of age less than or equal to 28 days. Outbreak
cases were defined by isolation of an ESBL-Kp strain from
any culture of infected neonates in the NICU. Infection
was defined by clinical and laboratory criteria and require-
ment for antimicrobial therapy, while, colonization by the
absence of relevant symptoms. We note that no routine
screening for ESBL-Kp has been performed in the NICU
before the onset of the outbreak because infections caused
by these microorganisms were very rare in the NICU
(Petinaki, unpublished data).
Identification of isolates and antimicrobial susceptibility
testing
Identification to the species level and antimicrobial sus-
ceptibility testing of the isolates has been performed by
the Vitek-2 Advanced Expert system (BioMerieux Inc.,
Marcy l’ Etoile, France), according to the interpretive cri-
teria of the Clinical and Laboratory Standards Institute-
CLSI [12]. Phenotypic screening for ESBL production was
performed by the double-disk synergy test (DDST) and for
carbapenemase production by the meropenem-boronate
combined disk test, as described previously [3,13].
Bacterial isolates and surveillance cultures
Overall, a total of 64 non-carbapenemase-producing ESBL-
Kp collected from March to December 2012 in UHL
were analyzed; 26 of them were consecutively recovered
from various clinical specimens in the NICU, whereas
the remaining isolates (n = 38) were randomly collected
from different wards of the hospital during the same
period, so as to further investigate the extent and the
epidemiology of the outbreak.
During September to December 2012, repeated surveys
of rectal and pharyngeal swabs were obtained from neo-
nates on a weekly basis. Screening of nursing staff andenvironmental contamination by ESBL-Kp was also car-
ried out. All aforementioned surveillance cultures (1258
cultures in total) were directly inoculated on MacCon-
key agar plates. Recovered ESBL-Kp organisms were
stored at −80°C in Trypticase Soy Broth containing 10%
(v/v) glycerol for further analysis.
Detection of beta-lactamase and virulence genes
Total DNA from all ESBL-Kp was extracted using the
Quick-gDNA TM MiniPrep kit (ZYMO RESEARCH
Corp., USA). Detection by PCR of beta-lactamase (bla)
genes encoding KPC-, VIM-, TEM-, OXA- and CTX-M-
type enzymes was performed, as described previously [14].
The intrinsic SHV-1 and SHV-5-type enzymes were differ-
entiated by PCR, as described previously [15]. Sequences of
the PCR products were determined in both strands. Pro-
duction of the respective beta-lactamases was confirmed by
isoelectric focusing (IEF) [14]. The presence of the fimH,
ugeE, wabG, ureA, magA, allS and rmpA virulence genes
was assessed by PCR, as described previously [16].
Genotyping and phylogenetic analysis
Molecular typing was performed by BOX-PCR and Multilo-
cus Sequence Typing (MLST), as described previously
[17,18]. Allele numbers and sequence types (STs) were
assigned and new STs were deposited on the Institut Pasteur
France K. pneumoniae MLST database (www.pasteur.fr/
mlst). Phylogenetic analysis was performed by the neighbor-
joining tree algorithm using the MEGA software [19].
Collection of clinical data
Before obtaining the clinical information of the neo-
nates, approval was received by the Ethics Committee of
the UHL, which is represented by the Infection Control
Committee (number of permission 1234). Clinical re-
cords from the neonates were collected and reviewed in-
cluding the following data: date and place of birth, date
of admission in the NICU, length of stay in the NICU,
birth weight, sex, vaginal or caesarean delivery, gesta-
tional age, age (days after birth) at first isolation of
ESBL-Kp, surgical procedures, intubation, use of central
venous catheters, placement of chest tubes, parenteral
nutrition, antimicrobial therapy and use of intralipids.
Results and discussion
Outbreak description and infection control interventions
The onset of the outbreak was recognised on the 5th
March 2012 when two ESBL-Kp isolates were recovered
from the blood and urine samples of two twin neonates
born at the maternity unit of the UHL. These isolates were
recovered on the 13th and 18th day after admission of the
twins in the NICU, suggesting acquisition of these isolates
in the NICU. Another case was detected on the 30th
March and two more cases at the beginning of April.
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and two nurses) was formed to coordinate the manage-
ment of the outbreak, providing specific recommendations,
such as cohorting of infants, limited rotation of the staff,
encouraging effective hand hygiene, safe disposal of diapers
into specific bags, daily cleaning of the surfaces and soiled
articles with soap and water, followed by disinfection with
a dilute solution of chlorine containing bleach and chlor-
hexidine (Acrylan, Kosmidis Company, Athens, Greece).
No new cases were detected between May and June, and
despite the control measures, three new cases were de-
tected from July to August 2012. During this period, we
noted that the ratio of nurse/patients was 1:7 at the time of
the outbreak because of understaffing because of summer
leaves (usual ratio, 1:4). Thus, from March to August 2012,
a total of 8 ESBL-Kp were detected in an equal number
of neonates.
On the 1st September 2012, a surveillance protocol was
implemented for all neonates affected by ESBL-Kp in a
weekly basis. From September to December 2012, five
more infected neonates were identified, whereas 13 ESBL-
Kp were recovered from 12 colonized infants. Four ESBL-
Kp were recovered from blood cultures within the first
three weeks of November, and therefore infection control
measures were intensified. On the 1st December, three co-
horts of infants were established: the first group included
all infants infected or colonized with ESBL-Kp which were
cared for by designated nurses and placed on contact pre-
cautions until hospital discharge in a separate nursery, the
second group included infants with exposure to case-
infants, but with negative surveillance cultures, which
were cared for by another group of designated nurses,
and a third group of newly admitted infants were cared
for in a separate room by another group of designated
nurses. Furthermore, the antibiotic policy in the NICU has
changed; restriction of third-generation cephalosporins
was enforced and imipenem was used for infants with sus-
pected sepsis. Multidisciplinary meetings were held twice
weekly to discuss the ongoing investigation and compli-
ance with the infection control measures. From September
to December 2012, a total of 18 ESBL-Kp were detected
in 5 infected and 12 colonized neonates.
ESBL- Kp have not been isolated from the hands of
the nursing staff and environmental samples. No other
cases were detected until now and we assumed that the
outbreak was successfully controlled.
Characterization of beta-lactamase and virulence
gene content
All 26 neonatal ESBL-Kp were positive only for both the
SHV-5 and TEM-1 beta-lactamases, as shown by PCR
and IEF. Among the 38 ESBL-Kp collected from other
wards of the hospital, 18 isolates were SHV-12 (n = 12)
or SHV-5 (n = 6) producers, 19 isolates were CTX-M-15(n = 16) or CTX-M-3 (n = 3) producers and one isolate
coproduced SHV-5 and CTX-M-15. All neonatal ESBL-
Kp were also positive for the presence of fimH, ugeE,
wabG and ureA, but negative for the magA, allS and
rmpA virulence genes.
Antimicrobial susceptibility testing and molecular typing
The 64 ESBL-Kp were assigned to 15 different BOX-PCR
profiles. Among 32 representative isolates of the major
BOX-PCR profiles and all the isolates with unique profiles,
we have identified 13 MLST STs; five of them were novel
STs. The antimicrobial susceptibility patterns of the iso-
lates and the STs of the four major BOX-PCR profiles
identified among the 64 ESBL-Kp are shown in Table 1.
All neonatal ESBL-Kp displayed multidrug-resistance
phenotypes, including resistance to penicillins, ceftazidime,
and aztreonam, tobramycin and gentamycin (Table 1).
ST20 (BOX-PCR pattern P1) was identified among 16
ESBL-Kp recovered from 13 infected and three colonized
neonates. ST20 has been previously identified among new-
borns affected by ESBL-Kp, which produced CTXM-15 in
Spain [20]. A novel ST (ST1114) was identified in nine neo-
nates colonized by ESBL-Kp (n = 10) of the BOX-PCR pat-
terns P2 (n = 8), P3 (n = 1) and P4 (n = 1) (Figure 1). The 38
ESBL-Kp recovered from the other wards of UHL were dis-
tributed into two major clusters, P5 (n = 12) and P6 (n =
16) profiles (Table 1, Figure 1), which were assigned to
ST258 and ST101, respectively. ST258 has been identified
mostly among carbapenemase-producing K. pneumoniae
worldwide (including Greece), whereas ST101 has been
previously reported among carbapenemase-producing K.
pneumoniae in Italy and Korea [3,21-23].
Neonatal ESBL-Kp of ST20 and ST1114 were not gen-
etically related, each comprising a separate lineage on
the neighbor-joining tree (Figure 1). Furthermore, ST20
and ST1114 were not found among non-carbapenemase-
producing ESBL-Kp recovered from other wards of the
hospital. Although SHV-5 producers were distributed into
six different MLST STs, there was no genetic relatedness
among the neonatal and the other strains (Figure 1).
Therefore, transmission of SHV-5 producers from the
NICU to other wards, or vice versa, was not documented.
The differences in the antibiotic resistance profiles of
the neonatal ESBL-Kp with those recovered from other
wards of the hospital (Table 1) and the presence of two
distinct bacterial clones among ESBL-Kp in the NICU, the
ST20 and ST1114 clones (corresponding to BOX-PCR
profiles P1 and P2, respectively), which were not genetic-
ally related to each other or other ESBL-Kp isolated from
other wards of the hospital (Table 1, Figure 1), indicate
that ESBL-Kp should have been imported in two different
occasions and disseminated only in the NICU.
As all of the infected neonates and only three colonized
neonates were affected by ST20 ESBL-Kp, we considered
Table 1 Antimicrobial susceptibility patterns of the four major BOX-PCR profiles of ESBL-Kp in a NICU, Larissa, Greece
BOX-PCR
profilea
MLSTST MIC range (mg/L)b
AMP AMP/SUL CTX CAZ ATM IMP MER ERT CIP TOB GM TSX
NICU (n = 26)
P1 (16) ST20 ≥32 ≤2− 16 ≤1− ≥64 8- ≥64 8- ≥64 ≤1 ≤0.25 ≤0.5 ≤0.25 ≥16 ≥16 ≤20
P2 (8) ST1114 ≥32 ≤2 ≤2− ≥64 16- ≥64 4- ≥64 ≤1 ≤0.25 ≤0.5 ≤0.25 ≥16 ≥16 ≤20
Non-NICU (n = 38)
P5 (12) ST258 ≥32 8- ≥32 16 ≥64 ≥64 ≤1 ≤0.25 ≤0.5 ≥4 ≤1-16 ≥16 ≤20- ≥320
P6 (16) ST101 ≥32 ≥32 ≥64 16- ≥64 32- ≥64 ≤1 ≤0.25 ≤0.5 ≥4 8- ≥16 ≤1-8 ≤20- ≥320
aIn parenthesis, the number of isolates identified in each of the four major BOX-PCR profiles is shown.
bAMP: ampicillin, AMP/SUL: ampicillin/sulbactam, ATM: aztreonam, CAZ: ceftazidime, CIP: ciprofloxacin, CTX: cefotaxime, ERT: ertapenem, GM: gentamycin, IMP:
imipenem, MER: meropenem, TOB: tobramycin, TSX: trimethoprim/sulfamethoxazol.
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the NICU. The time-course of the outbreak of ST20
ESBL-Kp is shown in Figure 2. ESBL-Kp of ST1114 were
identified in the NICU from September to December
2012, when surveillance cultures were obtained from the
neonates. However, we cannot exclude the possibility that
the ST1114 ESBL-Kp were circulating in the NICU among
colonized infants before the surveillance period. Neverthe-
less, we were not able to identify the source of the import-
ation of ESBL-Kp in the NICU, as no ESBL-Kp were
isolated either from the hands of the nursing staff or theFigure 1 Neighbor-joining tree of the STs of the 32 representative ES
beta-lactamase content are indicated.environment. It could be hypothesized that some of the
mothers of the neonates were carriers of ESBL-Kp and
that they were the source of the neonatal infections or col-
onizations. However, screening for colonization of the
mothers of the neonates was not performed in this study.
Clinical characteristics of the outbreak
A retrospective review of clinical data of the neonates af-
fected ESBL-Kp was performed (Table 2). Of the 16 (13
infected and three colonized) neonates affected by the out-
break strain of ST20 ESBL-Kp, 11 neonates were born inBL-Kp. For each isolate, the MLST ST, the BOX-PCR profile and the
Figure 2 Time-course of the outbreak of ST20 ESBL-Kp. The sex (F: female, M: male) and the infection (I) or colonization (C) status of each
infant is indicated. Case 4, indicated with a different colour scheme, has died. The time of first isolation of ST20 SHV-5 producers for each infant is
indicated with an asterisk.
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nates were admitted to UHL from the general hospital of
Larissa or different private maternity clinics of the prefec-
ture of Thessaly. One infected neonate has died. Fourteen
of the 16 neonates were delivered by caesarean section
and they showed low gestational age (≤32 weeks) and low
birth weight (≤1500 g). All neonates had received paren-
teral nutrition. Several risk factors, such as intubation
(n = 13), placement of central venous catheters (n = 11)
and chest tubes (n = 4) were also documented. Low gesta-
tional age, low birth weight and use of invasive devices
have been reported previously among the risk factors for
acquiring ESBL-producing Enterobacteriaceae in NICUs
[6,24-27].
As mentioned previously, of the 25 neonates affected by
ESBL-Kp and 16 neonates affected by ST20 ESBL-Kp, 13
(52% and 81.2%, respectively) developed an infection,
whereas ST1114 was identified only among colonized pa-
tients (Table 2). Thus, ST20 ESBL-Kp showed high infec-
tiousness compared with ST1114 ESBL-Kp. Furthermore,
four out of 16 (25%) ST20 ESBL-Kp were recovered from
bloodstream infections. These observations could be at-
tributed to differences either in the virulence potential of
the STs or in the clinical characteristics of the infants af-
fected by ST20 and ST1114 ESBL-Kp. No differences inthe virulence gene content among ESBL-Kp belonging to
ST20 and ST1114 were observed, but several other viru-
lence characteristics (e.g. the mucoid phenotype, aerobac-
tin production, capsular serotype) are associated with the
type of infection in K. pneumoniae, as reported previously
[28]. As shown in Table 2, no differences in the clinical
characteristics of the neonates affected by ST20 and
ST1114 ESBL-Kp were observed.
In our study, surveillance cultures were obtained during
the outbreak period (from September- December 2012).
The percentage of new carriers out of the total amount
that were screened during the out break period (12 colo-
nized infants out of 62 infants screened from September
to December 2012) was 19.35%. Surveillance has stopped
by the end of December of 2012, as no new infections by
ESBL-Kp were detected after the end of December 2012
and onwards, only a small percentage of ST20 ESBL-Kp
were detected in colonized infants (3 out of 16 ST20
ESBL-Kp) during the outbreak period, and no infections
were caused by ST1114 ESBL-Kp. The best time to screen
neonates is arguable and high compliance with the surveil-
lance protocol is essential for success. Nevertheless, it has
been shown recently that continuous long-term surveil-
lance and neonatal cohorting are associated with a marked
decrease in the spread of ESBL-KP within the NICU [27].
Table 2 Clinical characteristics of the neonates affected by ESBL-Kp in a NICU, Larissa, Greece

















Neonates affected by ST20 ESBL-Kp
1 February 23 February 23 27 10 120 1000 M Inborn ET Infected CS PN, IT,CVC Discharged
2 February 23 February 23 27 10 85 1070 F Inborn Urine Infected CS PN, IT,CVC Discharged
3 March 17 March 17 31 13 21 1220 F Inborn Urine Infected CS PN Discharged
4 March 28 March 28 26 34 145 790 F Outborn ET Infected CS PN, IT, CVC Died
5 April 19 April 20 38 4 35 3380 M Outborn ET Infected CS PN, IT, CVC, CT Discharged
6 July 8 July 8 32 11 34 1360 F Outborn Eye Infected CS PN, IT, Discharged
7 August 6 August 6 28 3 70 1255 F Inborn Catheter Infected CS PN, IT, CVC, CT Discharged
8 August 6 August 6 28 11 55 1000 F Inborn ET Infected CS PN, IT, ET, CVC Discharged
9 August 31 August 31 28 22 154 800 M Inborn FC Colonized CS PN, IT, CVC Discharged
10 October 13 October 13 28 35 126 960 M Inborn FC Colonized CS PN, IT, CVC, CT Discharged
11 October 15 October 15 31 25 44 1500 M Inborn Blood Infected VD PN, IT, CVC Discharged
12 October 27 October 27 31 6 40 580 M Outborn Blood Infected CS PN, IT, CVC Discharged
13 October 31 October 31 28 20 93 1120 F Outborn Blood Infected CS PN, IT, CVC Discharged
14 November 2 November 2 30 7 40 1350 F Outborn Blood Infected CS PN Discharged
15 November 16 November 16 32 32 49 1365 F Inborn Urine Infected VD PN, IT Discharged
16 December 6 December 09 35 10 21 2270 M Outborn FC Colonized CS PN Discharged
Range: 26–38 Range: 3–35 Range: 21–154 Range: 580–3380
Mean: 30 Mean: 15.8 Mean: 70.8 Mean: 1313.8
Neonates affected by ST1114 ESBL-Kp
17 September 5 September 5 28 25 35 850 F Inborn FC Colonized CS PN Discharged
18 September 15 September 15 27 17 80 1000 M Outborn FC Colonized CS PN, IT, CVC Discharged
19 October 5 October 5 30 15 45 750 F Inborn FC Colonized CS PN Discharged
20 October 27 October 27 31 25 56 1000 F Inborn FC Colonized CS PN,CVC Discharged
21 October 31 October 31 28 30 118 1040 F Outborn FC Colonized CS PN, ΙΤ,CVC Discharged
22 November 5 November5 28 12 114 980 F Outborn FC Colonized VD PN, ΙΤ,CVC Discharged
23 November 15 November 15 27 35 90 1070 F Inborn FC Colonized VD PN, ΙΤ,CVC Discharged
24 December 22 December22 34 4 27 1480 F Outborn FC Colonized CS PN Discharged
25 December 28 December 28 31 2 27 1480 F Outborn FC Colonized CS PN Discharged
Range: 27–34 Range: 2–35 Range: 27–118 Range: 750–1480
Mean: 29.3 Mean: 18.3 Mean: 65.7 Mean: 1072.2
aF: female, M: male.
bET: endotracheal tube, FC: Fecal carriage.
cCS: caesarean section, VD: vaginal delivery.
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In the present study, we described an outbreak occurred
during a nine-months period in 2012 at the NICU of UHL
caused mainly by multidrug-resistant SHV-5 producers of
ST20 recovered from 13 infected and three colonized neo-
nates, whereas a novel ST (ST1114) was identified only
among colonized neonates. A retrospective study of the
clinical data of the neonates affected by ESBL-Kp has re-
vealed that all neonates had received parenteral nutrition
and most of them were delivered by caesarean section and
showed low birth weights. To our knowledge, this is the
first report of SHV-5 producers assigned to ST20. The
emergence of ST20 and ST1114 SHV-5 producers in the
NICU, along with the presence of various previously re-
ported STs (e.g. ST101, ST258) and six novel STs among
SHV-5/12 or CTXM-3/15 producers in other wards of
UHL indicate the ongoing evolution of ESBL-producing
K. pneumoniae in our area.
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